Neurolixis
France - CastresBiotechnology
Focus: Neurolixis is a French biotechnology company headquartered in Castres specializing in CNS treatments, currently in clinical development stage with a focused pipeline in neurology.
Profile data last refreshed 12h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Neurolixis
AI assessmentNot HiringNo open roles listed right now. Follow Neurolixis to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Neurolixis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 2
Clinical Trials (1)
NCT05148884Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
Phase 2Help build intelligence for Neurolixis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.